Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study | Beusterien et al. Health and Quality of Life Outcomes 2010 8 50 http content 8 1 50 I HEALTH AND QUALITY OF LIFE OUTCOMES RESEARCH Open Access Population preference values for treatment outcomes in chronic lymphocytic leukaemia a cross-sectional utility study Kathleen M Beusterien 1 John Davies2 Michael Leach3 David Meiklejohn4 Jessica L Grinspan1 Alison O Toole5 and Steve Bramham-Jones5 Abstract Background Given that treatments for chronic lymphocytic leukaemia CLL are palliative rather than curative evaluating the patient-perceived impacts of therapy is critical. To date no utility preference studies from the general public or patient perspective have been conducted in CLL. The objective of this study was to measure preferences for health states associated with CLL treatment. Methods This was a cross-sectional study of 89 members of the general population in the UK England and Scotland . Using standard gamble each participant valued four health states describing response status six describing treatment-related toxicities based on Common Toxicity Criteria and two describing line of treatment. The health states incorporated standardized descriptions of treatment response symptoms have improved stabilized or gotten worse swollen glands impact on daily activities fatigue appetite and night sweats. Utility estimates ranged from reflecting dead to reflecting full health. Results Complete response CR was the most preferred health state mean utility followed by partial response PR no change NC and progressive disease PD . Among the toxicity states grade I II nausea and nausea vomiting had the smallest utility decrements both were and grade III IV pneumonia had the greatest decrement . The utility decrements obtained for toxicity states can be subtracted from utilities for CR PR NC and PD as appropriate. The utilities for second- and third-line treatments which are attempted when symptoms worsen were and .
